Clinical Trials
11 trialsNCT07296484 2026-05-12
CAPTAIN-T2D
Sparrow Pharmaceuticals
Phase 2 Recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT07104812 2026-02-11
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Mayo Clinic
Phase 2 Recruiting
NCT05307328 2025-10-08
RESCUE
Sparrow Pharmaceuticals
Phase 2 Completed
NCT06106295 2025-09-22
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Mayo Clinic
Phase 2 Active not recruiting
NCT07138274 2025-08-22
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Mayo Clinic
Phase 2 Not yet recruiting
NCT02468193 2020-05-06
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Novartis
Phase 2 Completed
NCT02804750 2019-10-15
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Phase 2 Completed
NCT00422201 2019-10-11
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
HRA Pharma
Phase 2 Terminated
NCT02780882 2018-01-26
SOM230 Ectopic ACTH-producing Tumors
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated